Progesterone receptor-dependent downregulation of MHC class I promotes tumor immune evasion and growth in breast cancer
Journal for ImmunoTherapy of Cancer · 2025-03 · 13 (3) · e010179
DOI: 10.1136/jitc-2024-010179 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 18.03.2025. Verfasst von Julio C Tinoco und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cancer Biology, University of Kansas Medical Center, Kansas City, Kansas, USA. Hauptthemen laut MEDLINE: Receptors, Progesterone, Breast Neoplasms, Histocompatibility Antigens Class I, Tumor Escape. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 99 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, NIGMS NIH HHS, NIH/NCI Cancer Center.
Abstract (Originalsprache)
Background
Breast cancer (BC) continues to be a major health concern with 250,000 new cases diagnosed annually in the USA, 75% of which are hormone receptor positive (HR+), expressing estrogen receptor alpha (ER) and/or the progesterone receptor (PR). Although ER-targeted therapies are available, 30% of patients will develop resistance, underscoring the need for new non-ER/estrogen-based treatments. Notably, HR+BCs exhibit poor lymphocyte infiltration and contain an immunosuppressive microenvironment, which contributes to the limited efficacy of immunotherapies in HR+BC. In this study, we demonstrate that PR/progesterone signaling reduces major histocompatibility complex (MHC) Class I expression, facilitating immune evasion and escape from immune-based clearance of PR+tumors.
Methods
To determine the effect of PR/progesterone on MHC Class I expression, we treated human and mouse mammary tumor cell lines with progesterone and/or interferon (IFN) and measured expression of genes involved in antigen processing and presentation (APP), as well as surface MHC Class I expression. We used the OT-I/SIINFEKL model antigen system to measure the impact of progesterone on immune cell-mediated killing of modified tumor cells. We also analyzed two large BC clinical cohorts to determine how PR expression correlates with APP gene expression and MHC Class I expression in ER-positive tumors.
Results
In vitro, we show that PR/progesterone signaling reduces APP gene expression and MHC class I expression in human and breast mammary tumor cell lines. PR-mediated attenuation of APP/MHC Class I expression is more pronounced in the presence of IFN. In immune cell killing assays, PR-expressing mammary tumor cells treated with progesterone are protected from immune-mediated cytotoxicity. We demonstrate that PR expression in vivo prevents immune-mediated rejection of xenoantigen-modified mammary tumor cell lines through mechanisms involving MHC Class I expression and CD8 T cells. Data analysis of two large BC cohorts reveals lower APP gene expression and MHC Class I expression in ER/PR-positive tumors compared with ER-positive/PR-negative tumors. These findings show that HR+BCs, specifically PR+tumors, downregulate APP/MHC class I machinery through PR/progesterone signaling. Use of pharmacological PR/progesterone inhibitors may reverse these effects in patients with BC, thereby improving immunosurveillance and response to immunotherapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cancer Biology, University of Kansas Medical Center, Kansas City, Kansas, USA.
- Biochemistry and Molecular Biology, University of Kansas Medical Center, Kansas City, Kansas, USA.
- Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
- Biostatistics and Data Science, University of Kansas Medical Center, Kansas City, Kansas, USA.
- Department of Oncological Sciences, University of Utah, Salt Lake City, Utah, USA.
- Department of Surgery, Duke University, Durham, North Carolina, USA.
Förderung
- NCI NIH HHS
- NIGMS NIH HHS
- NIH/NCI Cancer Center
- NIGMS
- ACS
- Breast Cancer Alliance
- University of Kansas Medical Center Flow Cytometry Core Laboratory
- NIH/NIGMS
Zitieren
APA
Tinoco, J. C., Saunders, H. I., Werner, L. R., Sun, X., Chowanec, E. I., Heard, A., Chalise, P., Vahrenkamp, J. M., Wilson, A. E., Liu, C. X., Lei, G., Wei, J., Cros, H., Mohammed, H., Troester, M., Perou, C., Markiewicz, M. A., Gertz, J., Balko, J. M., …, & Hagan, C. R. (2025). Progesterone receptor-dependent downregulation of MHC class I promotes tumor immune evasion and growth in breast cancer. Journal for ImmunoTherapy of Cancer, 13(3), e010179. https://doi.org/10.1136/jitc-2024-010179
Vancouver
Tinoco JC, Saunders HI, Werner LR, Sun X, Chowanec EI, Heard A, et al. Progesterone receptor-dependent downregulation of MHC class I promotes tumor immune evasion and growth in breast cancer. Journal for ImmunoTherapy of Cancer. 2025;13(3):e010179. doi:10.1136/jitc-2024-010179
BibTeX
@article{Tinoco2025,
author = {Tinoco, Julio C and Saunders, Harmony I and Werner, Lauryn Rose and Sun, Xiaopeng and Chowanec, Eilidh I and Heard, Amanda and Chalise, Prabhakar and Vahrenkamp, Jeffery M and Wilson, Andrea E and Liu, Cong-Xiao and Lei, Gangjun and Wei, Junping and Cros, Hugo and Mohammed, Hisham and Troester, Melissa and Perou, Charles and Markiewicz, Mary A and Gertz, Jason and Balko, Justin M and Hartman, Zachary Conrad and Hagan, Christy R},
title = {Progesterone receptor-dependent downregulation of MHC class I promotes tumor immune evasion and growth in breast cancer},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2025},
volume = {13},
number = {3},
pages = {e010179},
doi = {10.1136/jitc-2024-010179}
}
EUVIMED